THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Disease & Clinical Pharmacy Guides ARTICLE ID: KH-04 ⏱️ 9 min read 📅 Updated: 2026-11-10

Bronchial Asthma & COPD: GINA/GOLD Stepwise Pharmacotherapy & Inhaler Technique

🎯 Key Takeaways Summary

  • Instruct every patient using an Inhaled Corticosteroid (ICS) to rinse the mouth with water, gargle, and spit out after each dose to prevent oral candidiasis and dysphonia.
  • Never prescribe a LABA without an ICS in bronchial asthma.
  • Verify inhaler technique physically at every dispensing visit before escalating pharmacological step therapy.

1. Foundational Clinical & Scientific Overview

Modern asthma management (GINA Strategy) no longer recommends short-acting beta-2 agonist (SABA, e.g., Salbutamol) monotherapy because SABA-only treatment leaves airway eosinophilic inflammation unchecked and increases severe exacerbation risk. GINA recommends Inhaled Corticosteroid (ICS)–Formoterol (e.g., Budesonide + Formoterol) as both maintenance and reliever therapy (MART). In contrast, COPD management (GOLD Guidelines) relies primarily on long-acting bronchodilators (LAMA such as Tiotropium + LABA such as Formoterol/Indacaterol).

2. Core Mechanisms, Classification & Practical Framework

Inhaled drug delivery requires aerodynamic particle sizes between 1 and 5 micrometres to deposit in the lower conducting airways via sedimentation. Particles > 5 micrometres impact in the oropharynx (causing local hoarseness and oral candidiasis with ICS), while sub-micron particles (< 0.5 micrometres) are exhaled.

Structured Classification & Practical Examples

  • Inhaled Corticosteroids (Budesonide, Fluticasone Propionate, Beclomethasone): Suppress airway mucosal inflammation and upregulate beta-2 receptor expression.
  • Rapid-Onset LABA (Formoterol Fumarate) & Delayed-Onset LABA (Salmeterol Xinafoate): Relax bronchial smooth muscle via Gs-cAMP-PKA pathway (LABA monotherapy without ICS is contraindicated in asthma).
  • Long-Acting Muscarinic Antagonists — LAMA (Tiotropium, Glycopyrronium, Umeclidinium): Block M3 vagal bronchoconstriction; cornerstone of COPD maintenance.
  • Short-Acting Relievers: Salbutamol / Levosalbutamol (SABA) and Ipratropium Bromide (SAMA).
  • Leukotriene Receptor Antagonists (Montelukast): Block CysLT1 receptors; carry a neuropsychiatric warning (vivid dreams, mood changes).

3. Advanced Clinical Pharmacy, Dosing & Indian Regulatory Application

Device Selection & Counselling Protocol: Pressurised Metered-Dose Inhalers (pMDIs) require slow, deep inhalation (30 L/min over 3–5 seconds) coordinated with actuation, followed by a 10-second breath-hold; attaching a valved holding chamber (spacer) eliminates hand-breath coordination errors and reduces oropharyngeal steroid deposition by > 70%. Dry Powder Inhalers (DPIs / Rotahalers) are breath-actuated and require a rapid, forceful, deep inhalation (>= 60 L/min); never exhale into a DPI as moisture clumps the micronised lactose-drug blend.

4. Common Misunderstandings & Pharmacist Safety Safeguards

⚠️ Clinical Pitfall & Safety Note: Common Misunderstanding: Using Salmeterol + Fluticasone as an acute rescue inhaler. Unlike Formoterol (which has a rapid 1–3 minute onset suitable for MART), Salmeterol has a slow onset (15–30 minutes) and must never be used for acute bronchospasm relief.

5. Explanatory Visual Pharmacology Diagram (svg-v339-07-routes-of-drug-administration)

ROUTE-SPECIFIC DRUG DELIVERY: ONSET, BIOAVAILABILITY (F) & FIRST-PASS BYPASS 1. Oral (PO) • Onset: 30–90 min • F: Variable (5–99%) • First-Pass: YES (High) Safest, convenient; requires dissolution & portal transit. 2. Sublingual (SL) • Onset: 1–3 min (Rapid) • Drains to SVC directly • First-Pass: BYPASSED e.g. Sublingual GTN 0.5 mg in acute angina pectoris. 3. Buccal Route • Onset: 3–10 min • Cheek pouch mucosa • First-Pass: BYPASSED e.g. Buccal Midazolam, Buprenorphine, Fentanyl. 4. Intravenous (IV) • Onset: 15–60 sec • Bioavailability F = 100% • First-Pass: BYPASSED Strict asepsis & tonicity; irreversible once injected. 5. Intramuscular (IM) • Onset: 10–20 min • F: 75–100% • First-Pass: BYPASSED Deltoid / Vastus lateralis; oily depot formulations. 6. Subcutaneous (SC) • Onset: 15–30 min • Slow sustained absorption • First-Pass: BYPASSED Insulins, Enoxaparin (LMWH); rotate injection sites. 7. Inhalational • Onset: 2–5 min • Particle size 1–5 μm • Targeted Pulmonary Salbutamol, ICS; rinse mouth after ICS to prevent thrush. 8. Transdermal Patch • Onset: Hours (Steady) • Stratum corneum barrier • First-Pass: BYPASSED Fentanyl, GTN, Nicotine, Rivastigmine patches. 9. Topical / Ophthalmic • Local skin/mucosal effect • Minimal systemic toxicity • Nasolacrimal occlusion Timolol eye drops bypass first-pass if absorbed systemically. 10. Rectal (PR) • Onset: 5–30 min • Useful in vomiting/seizure • ~50% First-Pass Bypass Rectal Diazepam in paediatric febrile status epilepticus.
8.7 Route-Specific Drug Delivery: Bioavailability, Onset & First-Pass Comparison Across 10 Routes: Figure 8.7: Comparative biopharmaceutics across 10 routes of administration: Oral, Sublingual, Buccal, Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Inhalational, Transdermal, Topical, and Rectal.

6. Authoritative References & Editorial Traceability

Primary Reference Sources: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) by Tejas Nartam; ICMR Standard Treatment Workflows; NFI & NLEM 2022.

Official Portals: CDSCO • Indian Pharmacopoeia Commission (IPC / NFI) • ICMR • FSSAI • NCBI Bookshelf

Educational Disclaimer: Published for pharmacy education, academic learning, and professional clinical reference. Never self-medicate or alter prescribed treatment without consulting a qualified medical practitioner.

← Previous: Heart Failure with Reduced Ejection Fracti... All 40 Articles Next: Antimicrobial Stewardship in India: WHO AW... →